MOLECULAR CHARACTERIZATION AND THERAPEUTIC TARGETING OF TFE3 FUSION KIDNEY CANCERS...NEW AWARD. DISTRIBUTED ON 8/19/2019

Sloan-Kettering Institute For Cancer Research

Investigators